AstraZeneca’s Imfinzi success unlocks sizable opportunities for the company in lung cancer market, Merck to face a tough dominance battle
Category: #health  By Shikha Sinha  Date: 2017-05-16
  • share
  • Twitter
  • Facebook
  • LinkedIn

AstraZeneca’s Imfinzi success unlocks sizable opportunities for the company in lung cancer market, Merck to face a tough dominance battle

AstraZeneca, the renowned pharmaceutical magnate, has set a new benchmark in the cancer immunotherapy space, post the positive inferences unveiled by the company pertaining to its drug dubbed Imfinzi or Durvalumab. The drug successfully passed the phase III Pacific Lung Cancer Trial last week, followed by which the drug giant announced the positive results of the medicine, highlighting that it significantly reduced the worsening of the disease and death instances. The drug may likely serve as an alternative to chemotherapy, however, the trials were held post radiation therapy or chemotherapy.

This announcement has not only boosted the company’s share but has also given it a lead over its rivals such as Merck and Roche. Reportedly, earlier this year, Merck’s Keytruda was approved by U.S. Food and Drug Administration (FDA) for immunotherapy alongside chemotherapy. Allegedly, Merck had received a kind of initial approval for Kytruda back in October 2016, which allowed the disease to target only a subset of patients. However, the latest FDA approval has set new opportunities for the pharmaceutical conglomerate, giving it an access to nearly 90% of the newly diagnosed non-small-cell lung-cancer-patients.

Reports cite that the positive results of Imfinzi are sure to help AstraZeneca in its battle for dominance in the overall lung cancer market. The company is betting big in the immuno-oncology space by showcasing the positive results of Durvalumab and mentioning it as a major inflection point. The testimony of the huge value that Imfinzi might add to the drug portfolio of AstraZeneca is the gain of 9.1% that the company recorded on Friday afternoon. On the same day, Merck and Roche recorded 1.5% fall and 0.9% rise in their shares respectively.

Reliable sources state that the drug may witness a market opportunity somewhere in the range of USD 1.75 billion and USD 3.5 billion, which will be quite an appreciable contribution to AstraZeneca’s drug business. It is poised to be widely accepted among patients for whom surgery is not a viable option.

The company is also in mid of the trial of its another drug- Mystic, which will check the feasibility of the medicine alongside other treatments. The results of this trial are anticipated to be revealed in mid- 2017. Industry Analysts claim the positive results of Imfinzi to have set a favorable ground for the trial results of Mystic.



About Author

Shikha Sinha

Email: [email protected]   

Shikha Sinha

Shikha currently manages content operations for a series of news and business portals including MSF, Algosonline, and the like. An electrical & electronics engineer by education, she has prior experience in content & technology writing, content marketing, market resea...

Read More

More News By Shikha Sinha

Taiwan’s Formosa Phase II commercialization to commence in 2019
Taiwan’s Formosa Phase II commercialization to commence in 2019
By Shikha Sinha

After having recorded an electricity generation capacity of 6.5 MW from Formosa I – Taiwan’s 1st commercial-scale offshore wind project, the country is all set to boost its capacity to approximately 120 MW by...

Verizon to hand out pink slips to nearly 15% of AOL-Yahoo workforce post the formal acquisition of Yahoo
Verizon to hand out pink slips to nearly 15% of AOL-Yahoo workforce post the formal acquisition of Yahoo
By Shikha Sinha

Yahoo’s sale to Verizon, which created waves of frenzy in the tech space last year, was slated to close officially in the middle of June. The deal, worth USD 4.48 billion was dubbed by industry experts to be one ...

Telematics to bring about a revolutionary transformation in the auto industry, IoT integrated platforms to mitigate road safety concerns
Telematics to bring about a revolutionary transformation in the auto industry, IoT integrated platforms to mitigate road safety concerns
By Shikha Sinha

A recent report debating on the subject of road and driver safety has apparently shed light on a concept that could possibly play a huge role in enhancing the safety of roads. Telematics, the superior brain child of info...